[1] |
WEN Ziqiang, LAN Junliang, ZHOU Bo, XU Qiwei.
PARP1 promotes the progression of hepatocellular carcinoma by regulating expression of POU2F2
[J]. China Oncology, 2024, 34(9): 848-856.
|
[2] |
XIAO Feng, XU Tonglin, ZHU Lin, XIAO Jingwen, WU Tianqi, GU Chunyan.
Significance of infiltration of M1 tumor-associated macrophages in hepatocellular carcinoma
[J]. China Oncology, 2024, 34(8): 726-733.
|
[3] |
ZHAO Haichao, GAO Qiang.
Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022
[J]. China Oncology, 2023, 33(4): 315-326.
|
[4] |
HU Keshu, LIU Wenfeng, ZHANG Feng, QUAN Bing, YIN Xin.
Mechanism of LINC00601 in regulating sensitivity of hepatocellular carcinoma cells to oxaliplatin chemotherapy
[J]. China Oncology, 2023, 33(1): 25-35.
|
[5] |
ZHOU Changshuai, YANG Yuechao, CUI Huanhuan, CHEN Lei, CHEN Xin, HAO Bin, TONG Tong, CAO Yiqun.
Prognostic factor analysis of surgical treatment for cerebellar metastases in 36 patients
[J]. China Oncology, 2022, 32(4): 357-362.
|
[6] |
CHENG Yicai, DU Zhenhua, FAN Zhijuan, FENG Lan, CAO Pengbo, ZHOU Gangqiao.
Plasma exosomal CD48 protein as a candidate diagnostic biomarker for hepatocellular carcinoma
[J]. China Oncology, 2022, 32(11): 1074-1083.
|
[7] |
GUO Tao, SONG Ning, SUN Yuqi, TIAN Jiaqi, TANG Jie, SUN Rongqi, JIANG Yingying.
Effect of long non-coding RNA LINC00671 on biological behavior of hepatocellular carcinoma and its mechanism
[J]. China Oncology, 2022, 32(10): 990-999.
|
[8] |
WANG Zezhou , ZHANG Yang , MO Miao , YUAN Jing , ZHOU Changming , SHEN Jie , FENG Xiaoshuang , WU Haoxuan , LI Hang , YE Ting , HU Hong , CHEN Haiquan , ZHENG Ying .
Distribution of metastatic sites and survival analysis of patients with non-metastatic lung cancer at initial diagnosis based on hospital registration
[J]. China Oncology, 2021, 31(9): 775-782.
|
[9] |
XIAO Feng , XIAO Jingwen , SHAO Jianguo , CHEN Liyan , GU Chunyan .
The expression of programmed death 1 in tumor-infiltrating lymphocytes of hepatocellular carcinoma and its correlation with prognosis
[J]. China Oncology, 2021, 31(5): 419-427.
|
[10] |
NIU Na, LIN Yansong.
Application and research progress of selective internal radiation therapy with 90 Y microspheres in hepatocellular carcinoma
[J]. China Oncology, 2021, 31(5): 428-434.
|
[11] |
LIU Min , CHEN Tianliang , GUO Juan , YI Xue , GAO Hongquan , WU Jiacui , WANG Yuxiao .
Protein kinase Cβ Ⅱ promotes invasion of hepatocellular carcinoma by modulating autocrine of IL-6
[J]. China Oncology, 2021, 31(4): 268-276.
|
[12] |
ZHANG Jun , DONG Yuhua , YANG Ye , ZHANG Mengqi , HE Chang .
A novel strategy of regorafenib in combination with TAS102 against hepatocellular carcinoma
[J]. China Oncology, 2021, 31(4): 294-301.
|
[13] |
ZHANG Xin , ZHOU Cheng , ZHOU Kaiqian , BAI Qianming , JIANG Dongxian , SUJIE Akesu , HOU Yingyong , WANG Zheng , JI Yuan .
MET gene amplification and its prognostic role in sarcomatoid hepatocellular carcinoma
[J]. China Oncology, 2020, 30(9): 641-649.
|
[14] |
XU Shanshan , SONG Qinqin , WU Hongjiao , FU Ning , CHE Lingyu , JIN Min , LIU Chong , HAN Sugui , ZHANG Xuemei , ZHANG Zhi .
Genetic variation in membrane cofactor protein CD46 rs1970530 affects the risk of hepatocellular carcinoma
[J]. China Oncology, 2020, 30(9): 656-660.
|
[15] |
OUYANG Xiaochun , ZOU Yeqing , LI Yumei , DING Xiaobing .
ARHGAP4 promotes growth of hepatocellular carcinoma cells by regulating HK2 expression
[J]. China Oncology, 2020, 30(7): 481-487.
|